Free Trial

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company logo
$147.72 -0.03 (-0.02%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
8
Buy
7

Based on 16 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 1 has given a sell rating, 8 have given a hold rating, and 7 have given a buy rating for BDX.

Consensus Price Target

$184.86
25.14% Upside
According to the 16 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $184.86. The highest price target for BDX is $232.00, while the lowest price target for BDX is $159.00. The average price target represents a forecasted upside of 25.14% from the current price of $147.72.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDX Analyst Ratings Over Time

TypeCurrent Forecast
5/27/25 to 5/27/26
1 Month Ago
4/27/25 to 4/27/26
3 Months Ago
2/26/25 to 2/26/26
1 Year Ago
5/27/24 to 5/27/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
11 Hold rating(s)
10 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$184.86$189.08$195.46$221.44
Forecasted Upside25.14% Upside25.94% Upside10.75% Upside26.92% Upside
Consensus RatingHoldHoldHoldHold

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Becton, Dickinson and Company Stock vs. The Competition

TypeBecton, Dickinson and CompanyMedical CompaniesBroader Market
Consensus Rating Score
2.38
2.30
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside25.13% Upside1,704.03% Upside15.04% Upside
News Sentiment Rating
Positive News

See Recent BDX News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/11/2026 DowngradeHold (C-)Sell (D+)
5/11/2026
Barclays PLC logo
Barclays
3 of 5 stars
Matt Miksic
Matt Miksic
2 of 5 stars
Boost TargetOverweight$202.00 ➝ $204.00+36.69%
5/8/2026Boost TargetEqual Weight$157.00 ➝ $161.00+5.35%
5/7/2026 Lower Target$215.00 ➝ $175.00+14.51%
5/7/2026 Boost Target$180.00 ➝ $190.00+24.32%
5/4/2026Lower TargetHold$189.00 ➝ $163.00+8.66%
4/17/2026Lower TargetNeutral$170.00 ➝ $159.00+2.65%
4/14/2026 Set Target$175.00+12.64%
4/10/2026Initiated CoverageBuyNeutral$167.00+8.41%
4/10/2026 UpgradeStrong SellHold
3/23/2026Lower TargetBuy$230.00 ➝ $180.00+15.17%
2/10/2026Lower TargetBuy$220.00 ➝ $190.00+10.70%
2/10/2026Lower TargetBuy$233.00 ➝ $232.00+36.22%
2/10/2026Lower TargetNeutral$190.00 ➝ $175.00+4.89%
1/5/2026Boost TargetNeutral$190.00 ➝ $207.00+6.30%
12/2/2025Boost TargetOverweight$197.00 ➝ $210.00+9.45%
5/2/2025DowngradeOutperformMarket Perform
5/1/2025DowngradeOutperformMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:14 PM ET.


Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 18, 2026. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • The current stock price is around $154, which may present a buying opportunity given analysts' recent price target increases.
  • Becton, Dickinson and Company has raised its full-year adjusted EPS guidance, indicating strong financial performance and growth potential.
  • The company returned approximately $2.3 billion to shareholders recently, including significant share repurchases, which can enhance shareholder value.
  • Recent product launches, such as the EnCor EnCompass biopsy system and the Revello Vascular Covered Stent, demonstrate the company's commitment to innovation and expanding its market presence.
  • With a focus on operational efficiency, Becton, Dickinson and Company has achieved substantial productivity improvements, which can lead to better profit margins over time.

Becton, Dickinson and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • The company is currently facing an FDA warning letter related to its El Paso facility, which could impact its reputation and operational capabilities.
  • Despite recent price target increases, some analysts have downgraded their ratings, indicating mixed sentiment in the market.
  • There are concerns regarding the company's debt levels, as it ended the quarter with net leverage above its long-term target, which could limit financial flexibility.
  • Recent adjustments to revenue growth expectations suggest that the company may face challenges in achieving its financial targets in the near term.
  • Market volatility and economic uncertainties could pose risks to Becton, Dickinson and Company's performance, affecting investor confidence.

BDX Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $184.86, with a high forecast of $232.00 and a low forecast of $159.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last year. There is currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDX, but not buy additional shares or sell existing shares.

According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 25.14% based on their 12-month stock forecasts.

Over the previous 90 days, Becton, Dickinson and Company's stock had 2 upgrades and 1 downgrade by analysts.

Becton, Dickinson and Company has been rated by research analysts at Argus, Barclays, Evercore, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Weiss Ratings, Wells Fargo & Company, and Zacks Research in the past 90 days.

Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating score for Becton, Dickinson and Company is 2.38 while the average consensus rating score for "medical" companies is 2.30. Learn more on how BDX compares to other companies.


This page (NYSE:BDX) was last updated on 5/27/2026 by MarketBeat.com Staff.
From Our Partners